Seeing Is Believing

Currently out of the existing stock ratings of Michael Ulz, 165 are a BUY (65.48%), 82 are a HOLD (32.54%), 5 are a SELL (1.98%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 49.14% that have a potential upside of 41.39% achieved within 202 days. Previously, Michael Ulz worked at BAIRD.
Michael Ulz’s has documented 485 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Financial Services, Industrials sectors.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 31-Jul-2026.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for IONS (IONIS PHARMACEUTICALS) at 11/2/2023. The price target of $45 was fulfilled within 1 day with a profit of $1.27 (2.9%) receiving and performance score of 29.04.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
$22.5 (12.33%)
Hold Since 03-May-2021
$173
$-9.5 (-5.21%)
$156
Hold Since 04-Feb-2021
$190
$7.5 (4.11%)
$190
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
Buy Since 17-Jul-2017
$166
$-16.5 (-9.04%)
$175
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?